Latest Biodefense Stories

PRINCETON, N.J., Sept. 21 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that it has been awarded an approximate $9.4 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). The grant will fund, over a five-year period, the development of formulation and manufacturing processes for vaccines, including...

ANNAPOLIS, Md., Sept. 1 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that management will present at the Rodman & Renshaw Annual Global Investment Conference 2009. The Company is scheduled to present on Thursday, September 10th, 2009 at 10:00 a.m. E.T. in the Hubbard Salon (5th Floor) at the New York Palace Hotel, New York. The presentation will be webcast...

ABERDEEN PROVING GROUND, Md., May 6 /PRNewswire/ -- The Baltimore Federal Executive Board (FEB) recognized three employees from the U.S. Army Edgewood Chemical Biological Center (ECBC) during its 2009 Excellence in Federal Career Awards program, held Friday, May 1 at Martin's West in Baltimore. The annual event recognizes federal employees for excellence in job performance during the previous year. Peter F. Annunziato of ECBC's Engineering Directorate, received a Gold Award in the...

- Company Presents Data on Cethromycin Showing In Vivo Efficacy against Tularemia - CHICAGO, March 19 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), a biopharmaceutical company developing cethromycin, a novel once-a-day antibiotic, to treat respiratory tract infections and to combat bioterror threats, announced today that it received notice from the Department of Defense (DoD) that it has exercised its option to award the Company $2.0 million under the...

WASHINGTON, March 18 /PRNewswire-USNewswire/ -- David P. Wright, Co-Chair of the Alliance for Biosecurity and Chairman and CEO of PharmAthene, Inc., testified today before the House Labor, Health and Human Services, and Education Appropriations Subcommittee on the critical importance of developing drugs, vaccines and other medical countermeasures needed to protect Americans from bioterrorism and other catastrophic health emergencies. Effective medical countermeasures for many of the...

TORONTO, Feb. 19 /PRNewswire/ - Defyrus Inc. today announced the signing an exclusive, worldwide license to a patent portfolio created by the United Kingdom's Defence Science and Technology Laboratory (Dstl) and licensed by Ploughshare Innovation Ltd, Dstl's commercialization company. These patents form the intellectual property foundation of the Company's vaccine product development programs. Defyrus and Ploughshare Innovation Ltd plan to expand their commercial interaction in 2009 to...

An overwhelming majority of postal workers elected not to be vaccinated when anthrax was sent through the U.S. Postal Service in 2001, researchers said. Researchers at the University of Pittsburgh Graduate School of Public Health said reactions from postal workers were shaped partially by fears of being guinea pigs, disagreements among public health agencies about whether the vaccine should be recommended, physician advice, low perceived risk of infection and conflicting reports from...

Corgenix to serve as subcontractor to Battelle for submission of proposals to U.S. Government for biodefense related programs DENVER, Jan. 26 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced a collaboration with Battelle, a Columbus, Ohio-based independent research and development organization whose business focus includes national security. Under the collaboration, Corgenix will...

When anthrax was sent through the U.S. Postal Service in 2001, an overwhelming majority of postal workers elected not to be inoculated with the available vaccine because of confusion and distrust, according to a University of Pittsburgh Graduate School of Public Health study. Although the FBI officially closed the case on the attacks this year, lingering suspicion and uncertainty remain, say study authors, which could influence the public's reactions to future emergencies.According to the...

KVISTGARD, Denmark, December 1 /PRNewswire-FirstCall/ -- Following a Request for Proposal issued in 2007 with the intent to procure an MVA-based, third generation smallpox vaccine, Public Works and Government Services Canada, on behalf of the Canadian Department of National Defence, has awarded a contract to Bavarian Nordic for the delivery of IMVAMUNE(R). The Canadian authorities intend to use IMVAMUNE(R) as part of the country's bio-preparedness programme. The contract...